VYNE Therapeutics announces dosing of first subject in Phase 2b trial of VYN201

VYNE Therapeutics announced that the first subject has been dosed in a Phase 2b trial evaluating VYN201 in subjects with either active or stable nonsegmental vitiligo. VYN201 is a novel pan-bromodomain and extra-terminal domain inhibitor designed for local administration. Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025. The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts compared to vehicle for 24 weeks. The primary efficacy endpoint of the trial is the proportion of subjects achieving an improvement in Facial Vitiligo Area Scoring Index of at least 50% from baseline at week 24 compared to vehicle, with additional secondary endpoints of F-VASI and Total VASI at weeks 24 and 52.